Wandercraft

Wandercraft operates at the intersection of medical devices, rehabilitation robotics, and industrial humanoids. Its core differentiation is a hands-free, self-balancing approach: Atalante X is designed for gait training in clinical settings, while Eve extends the same balance concept toward personal mobility. The company’s systems combine powered joints with real-time adaptive gait algorithms, allowing multidirectional movement without reliance on crutches or a walker. That focus distinguishes Wandercraft from more conventional wearable-assistance providers that primarily amplify movement or require external stabilization. The acquisition of Ekso Bionics on Oct 1, 2026 potentially broadens its reach in the exoskeleton market, although integration benefits and commercial performance remain unconfirmed. Wandercraft also differs from purely healthcare-focused competitors by developing Calvin-40 for industrial tasks and working with Renault and SAPA on deployment. The available peer data does not identify a reliable set of directly comparable named companies, so competitive ranking should be treated cautiously. Its $170.6 million in recorded funding, 24 investors, FDA clearance for Eve, and presence on the 2026 Next40 list indicate substantial scale for a private European robotics company, but adoption, reimbursement, and manufacturing economics remain key market tests.

Wandercraft’s trajectory shows a progression from early-stage exoskeleton development into a broader mobility and robotics platform. The company was founded in 2012 and raised seed and pre-seed capital in 2013 before reaching Series A in 2015, Series B in 2017, and a €40 million Series C in 2022. A €25 million European Investment Bank debt facility announced in 2024 added non-dilutive financing, followed by a $75 million Series D on Jun 6, 2025 led by Renault Group. Product development has advanced along three linked paths: Atalante X for rehabilitation centers, Eve for personal use, and Calvin-40 for industrial work. The 2025 launch of a personal exoskeleton prototype, NVIDIA collaboration for AI training and simulation, and Renault’s industrial partnership marked a shift beyond hospitals. FDA clearance in August 2026 and Eve’s North American launch on Sep 30, 2026 represent the clearest commercialization inflection point. The opening of Walk in New York in May 2025 supports market access and clinical engagement, while the acquisition of Ekso Bionics on Oct 1, 2026 could accelerate scale. Active hiring in Paris and New York and no reported layoffs point to continued expansion, though employee growth figures and revenue data are unavailable.